evipedia.ai
← Back

Lithium for Health & Longevity

Created on 10/29/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Lithium, a natural trace mineral and, in much larger amounts, a long-standing psychiatric medicine, is studied in small daily amounts to support the aging brain. More tap-water lithium tracks with fewer suicides and less dementia, but small trials disagree and the newest showed no clear memory benefit. Harms are documented at medical doses; at supplement doses they have not been shown, yet long-term data are thin. (Full Review)

Protocol

Nutritional microdose
1 mg elemental lithium daily
Suggested supplement doses span 0.3–5 mg
Low-dose prescription regimen
Serum 0.25–0.5 mEq/L
Lithium carbonate titrated to this level
Time of day
Once-daily evening dosing
Common practice, so any peak-related tremor or nausea falls during sleep
Time to effect
Cognitive differences, low-dose trial
12–24 months
Lithium carbonate in mild cognitive impairment
Cognitive differences, microdose trial
From 3 months
300 µg lithium daily in Alzheimer's disease
Population associations
Decades
Drinking-water lithium and lower dementia rates

Benefits

Contraindications
  • Severe renal impairment (creatinine clearance below 30 mL/min)
  • Known or suspected Brugada syndrome, including unexplained fainting or a family history of sudden unexplained death before age 45 (cardiology review required)
  • Pregnancy, particularly the first trimester
  • Breastfeeding
  • Known hypersensitivity to any inactive ingredient of the product
  • Significant cardiovascular disease or chronic volume or sodium depletion
    •
Key Interactions
  • Thiazide and loop diuretics (hydrochlorothiazide, furosemide): raise lithium levels and toxicity risk
  • ACE inhibitors and ARBs (lisinopril, losartan): raise lithium levels
  • NSAIDs, including over-the-counter ibuprofen and naproxen (also celecoxib): raise lithium levels, risking toxicity
  • Nitroimidazole antibiotics (metronidazole): raise lithium levels, risking toxicity
  • SGLT2 inhibitors (empagliflozin): lower serum lithium and may reduce its effect
  • GLP-1 receptor agonists (semaglutide): preceded lithium toxicity
  • Xanthines (theophylline, caffeine): lower lithium levels; stopping caffeine raised lithium levels
  • Alkalinizing agents (sodium bicarbonate, including over-the-counter antacids): lower levels, reducing effect
  • Serotonergic drugs and supplements (sertraline, St. John's Wort): can precipitate serotonin syndrome
  • Antipsychotics (haloperidol): nervous-system toxicity has been reported
  • Calcium channel blockers (verapamil): raise the risk of unsteady movement, tremor, nausea and ringing in the ears
  • Iodide preparations (potassium iodide): may produce hypothyroidism
  • Carbamazepine, phenytoin and methyldopa: increased adverse reactions of these drugs
  • Neuromuscular blocking agents (succinylcholine): may prolong paralysis after surgery
  • Low-salt diets, protracted sweating (endurance exercise) and diarrhea: reduce lithium tolerance and raise toxicity risk
  • Inositol supplements (myo-inositol): improved lithium-associated psoriasis
    •
Theoretical (inferred from mechanism)
  • 5-HTP and SAMe: could add serotonergic activity
  • Herbal diuretics (dandelion leaf): could raise lithium levels, risking toxicity
  • Ketogenic diets and extended fasting: could raise lithium levels, risking toxicity
  • Kelp and high-iodine supplements: additive thyroid suppression
    •

Risk & Side Effects

  • High:
  • Medium: Lithium toxicity; Hypothyroidism; Impaired urine concentration and chronic kidney disease; Hyperparathyroidism and hypercalcemia; Weight gain; Tremor, diarrhea and fatigue; Congenital heart malformations; Autism risk after prenatal drinking-water exposure
    •
  • Low: Unmasking of Brugada syndrome; Sinus node dysfunction and bradycardia; Pseudotumor cerebri; Cognitive and motor slowing; Renal tumors; Skin and hair reactions
    •
  • Speculative: Orotate-specific kidney effects
    •

Monitoring

Marker Target Why
Serum lithium (12-hour trough) 0.25–0.5 mEq/L for low-dose prescription regimens Safety check and exposure marker
Serum creatinine 0.6–1.2 mg/dL Safety check: a rise reduces or stops use
eGFR Not specified in the ER Kidney-filtration trend
TSH 0.4–4.0 mIU/L A rise signals lithium-induced hypothyroidism
Free T4 Not specified in the ER Paired with TSH for thyroid function
Serum calcium 8.5–10.2 mg/dL A rise signals hyperparathyroidism
PTH Not specified in the ER Checks for hyperparathyroidism if calcium is elevated
Serum sodium 135–145 mmol/L Low sodium raises toxicity risk
Delayed verbal recall score No established target; track change from own baseline Marker the intervention is expected to change
Urinalysis Not specified in the ER Paired with creatinine for kidney checks
ECG Not specified in the ER Added when Brugada risk factors are present

Cadence: Baseline kidney function, electrolytes, thyroid function and calcium before starting. On prescription regimens, serum lithium three days after starting or any dose change, then regularly until stable; thyroid function at three months, then every 6–12 months; kidney function and calcium every 6–12 months. At supplement doses of 1–5 mg, yearly kidney and thyroid checks are the usual minimum.

Qualitative Assessment

  • Mood stability and irritability
  • Everyday memory and word-finding
  • Tremor, thirst and urination frequency (early toxicity or kidney signals)
  • Energy, cold intolerance and weight change (thyroid signals)
  • Gastrointestinal comfort, including diarrhea and nausea
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.